Cancer therapeutic targeting using mutant-p53-specific siRNAs

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• TP53 mutations are prevalent in over half of all cancers, often conferring resistance to therapy.
• Mutant p53 can exert dominant-negative effects on wild-type p53 or provide a survival advantage, leading to cancer cell addiction.
• Targeting mutant p53 is a promising strategy to overcome therapeutic resistance in various cancers.

Purpose of the Study:

• To develop and evaluate mutant-p53-specific small-interfering-RNAs (MupSi) for cancer therapy.
• To assess the specificity and efficacy of MupSi in silencing hot-spot p53 mutants.
• To investigate the therapeutic potential of MupSi in preclinical cancer models.

Main Methods:

• Generation of a series of small-interfering-RNAs (siRNAs) targeting common p53 hot-spot mutations.
• Assessment of siRNA specificity for mutant p53 versus wild-type p53.
• Evaluation of MupSi's functional effects on cancer cell death and tumor growth in xenograft models.

Main Results:

• Developed MupSi that specifically silence target mutant p53 alleles without affecting wild-type p53.
• Demonstrated that MupSi induce cancer cell death by disrupting mutant p53 addiction and dominant-negative effects.
• Observed significant tumor growth retardation in xenografts treated with MupSi, indicating therapeutic efficacy.

Conclusions:

• Mutant-p53-specific siRNAs (MupSi) represent a viable therapeutic approach for cancers harboring p53 mutations.
• MupSi effectively target mutant p53, leading to cancer cell death and reduced tumor progression.
• Targeting mutant p53 specifically holds promise for improving clinical outcomes in a broad range of cancers.